Loading...
FATE logo

Fate Therapeutics, Inc.Informe acción NasdaqGM:FATE

Capitalización bursátil US$262.3m
Precio de las acciones
US$2.25
US$5.41
58.4% infravalorado descuento intrínseco
1Y94.0%
7D28.2%
1D
Valor de la cartera
​
Ver

Fate Therapeutics, Inc.

Informe acción NasdaqGM:FATE

Capitalización de mercado: US$262.3m

Fate Therapeutics (FATE) Resumen de Acciones

Fate Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica que desarrolla inmunoterapias celulares programadas contra el cáncer y los trastornos inmunitarios en Estados Unidos y a escala internacional. Saber más

Análisis fundamental de FATE
Puntuación del snowflake
Valoración0/6
Crecimiento futuro2/6
Rendimiento pasado0/6
Salud financiera6/6
Dividendos0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 63.74%

Los beneficios han crecido un 9% al año en los últimos 5 años

Análisis de riesgos

Se prevé que los beneficios disminuyan un promedio de 4.8% al año durante los próximos 3 años

Precio de las acciones volátil durante los últimos 3 meses en comparación con el mercado US

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años


FATE Community Fair Values

Create Narrative

See what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Competidores de Fate Therapeutics, Inc.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Fate Therapeutics
Precios históricos de las acciones
Precio actual de la acciónUS$2.25
Máximo en las últimas 52 semanasUS$2.47
Mínimo de 52 semanasUS$0.91
Beta2.14
Cambio en 1 mes69.17%
Variación en 3 meses49.01%
Cambio de 1 año93.97%
Variación en 3 años-56.14%
Variación en 5 años-97.06%
Variación desde la OPV-66.01%

Noticias y actualizaciones recientes

Seeking Alpha • May 12

Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026

Summary Fate Therapeutics, Inc. is downgraded from Strong Buy to Hold due to slower-than-expected clinical progress in its FT819 program for SLE. Phase 1 FT819-102 study shows promising efficacy with significant SLEDAI-2K score reductions, but patient enrollment and expansion to Regimen B remain limited. Regulatory catalysts, including potential phase 2 registration-enabling study initiation, are not expected until 2H 2026, delaying near-term value inflection. FATE maintains strong cash reserves through 2027 and has reduced operating expenses, but clinical and regulatory risks persist across its pipeline. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • May 12

Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026

Summary Fate Therapeutics, Inc. is downgraded from Strong Buy to Hold due to slower-than-expected clinical progress in its FT819 program for SLE. Phase 1 FT819-102 study shows promising efficacy with significant SLEDAI-2K score reductions, but patient enrollment and expansion to Regimen B remain limited. Regulatory catalysts, including potential phase 2 registration-enabling study initiation, are not expected until 2H 2026, delaying near-term value inflection. FATE maintains strong cash reserves through 2027 and has reduced operating expenses, but clinical and regulatory risks persist across its pipeline. Read the full article on Seeking Alpha
Artículo de análisis • Nov 25

Here's Why We're A Bit Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Artículo de análisis • Aug 08

Here's Why We're Watching Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

NasdaqGM:FATE 1 Year Share Price vs Fair Value Explore Fate Therapeutics's Fair Values from the Community and select...
Artículo de análisis • Apr 22

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 05

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Summary Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma. But in my view, FT819 shows the most promising, as they recently achieved remission for one SLE patient. Valuation-wise, I think FATE’s low P/B relative to peers shows it is cheap, even though that’s partially due to its early-stage pipeline. The main risk I see with FATE is its inherently speculative R&D progress, but also its cash burn, which could become an issue by 2027. Other than that, I rate FATE a “Buy”. Read the full article on Seeking Alpha
Artículo de análisis • Jan 06

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 20

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Summary Fate Therapeutics, Inc. reported positive phase 1 data for FT819 in treating moderate-to-severe Systemic Lupus Erythematosus, showing remission in one patient with fludarabine-free conditioning. A second study arm will test FT819 as an add-on to maintenance therapy without conditioning chemotherapy targeting SLE patients. Data from the first three patients will be presented at the American Society of Hematology Annual Meeting, being held between December 7th through 10th of 2024. FT522 is also being explored in phase 1 trials for the treatment of patients with relapsed/refractory B-cell lymphoma and B-cell mediated autoimmune disorders. Read the full article on Seeking Alpha
Artículo de análisis • Aug 21

Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Fate Therapeutics, Inc. ( NASDAQ:FATE ) shareholders will have a reason to smile today, with the analysts making...
Artículo de análisis • Aug 11

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 29

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Summary Fate Therapeutics has faced setbacks, including the termination of a partnership with Janssen Pharmaceuticals, but upcoming clinical milestones could reset the bull thesis. The company's iPSCs technology creates renewable off-the-shelf cell therapies for hematological malignancies and solid tumors. Fate Therapeutics has a healthy cash position and is expected to report positive data from clinical trials, potentially leading to exponential growth and significant market share. Read the full article on Seeking Alpha
Artículo de análisis • Apr 23

Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares have retraced a considerable 28% in the last month, reversing a fair...
Artículo de análisis • Feb 16

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Despite an already strong run, Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares have been powering on, with a gain of 57...
Seeking Alpha • Jan 26

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Summary Fate Therapeutics is a cell therapy-focused biotech that is overvalued and should be sold due to the risk of value erosion in 2024. The company's most advanced pipeline projects are FT576 and FT819, but no updates have been provided since the last article. The transition of their HER2-targeted CAR T-cell product, FT825, into phase 1 study is a significant development, but early data is needed to determine its potential. Read the full article on Seeking Alpha
Artículo de análisis • Dec 19

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

The Fate Therapeutics, Inc. ( NASDAQ:FATE ) share price has done very well over the last month, posting an excellent...
Artículo de análisis • Sep 08

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Artículo de análisis • Jun 07

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

With a price-to-sales (or "P/S") ratio of 4x Fate Therapeutics, Inc. ( NASDAQ:FATE ) may be sending very bullish...
Artículo de análisis • May 08

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

Shareholders in Fate Therapeutics, Inc. ( NASDAQ:FATE ) may be thrilled to learn that the analysts have just delivered...
Artículo de análisis • Apr 17

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Artículo de análisis • Jan 10

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • Sep 22

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 30

Fate Therapeutics: Yes For Speculators, No For Defensive Investors

Summary Fate Therapeutics has potential inflection points stemming from clinical trial and regulatory momentum in the next 6-12 months. For those taking speculative positions within healthcare, this could present with potential upsides post-event(s). Those investors looking for a defensive overlay within healthcare might find weakness in FATE's measures of corporate value. With these points in mind, we rate FATE a hold with a $21 per share valuation. Investment summary There are selective opportunities located within the healthcare universe for investors taking both speculative and defensive positions. In either sense, factor rotations in H2 FY22 corroborate that value remains a thematic favorite for investors, adding a layer of resiliency to portfolios. Measures examining corporate value are therefore of upmost importance for equity investors looking ahead, in order to decipher the quality of earnings and business model one is allocating to. With this in mind, we examined Fate Therapeutics, Inc. (FATE) and found that it offers potential upsides from clinical trial and regulatory momentum over the next 6-12 months. For those on the speculative side, this is ideal. However, we also noted that for those seeking a defensive beta name in healthcare, FATE might not be the best choice, due to lack of profitability and unsupportive valuations from forward earnings. With opportunity costs front of mind, but also acknowledging the strengths in FATE's wider offering, we rate FATE a hold with a price target of $21. Exhibit 1. FATE 6-month price action Data: Refinitiv Eikon Q2 earnings indicative of regulatory, fundamental momentum Fundamental momentum is creeping up alongside regulatory momentum for FATE. Despite this, its earnings do need some cleaning up to reflect a more accurate snapshot. Revenue obtained via collaborations with Janssen and Ono Pharmaceutical (OPHLY) rose to $18.5 million in Q2 FY22, a 38% growth YoY. Meanwhile, the company saw a ~67% YoY headwind at the G&A line with expenditures increasing to $20.4 million. However, breaking down the increase in G&A, ~34% or $6.9 million ($0.07/share) was attributed to stock based compensation ("SBC"), up $4.3 million from this time last year. Operating expenses were also comprised of $81.3 million in R&D spend, that we argue should be capitalized and treated as an investment on the balance sheet [discussed later]. All in, SBC comprised $20.5 million of the $101.6 million in operating spend for the quarter. On the regulatory front, FATE achieved its first clinical milestone in its CAR T-cell product candidate, FT819. This is under an amended license agreement with Memorial Sloan Kettering Cancer Centre ("MSK"). The first milestone payment to MSK was activated following this milestone. This is important as there could be an additional 2 milestone payments obliged to MSK that are based on trading volumes of the company's stock in ranges of $100-$150/share. Changes in the fair value of these instruments is booked as income or expenditure by FATE and is therefore worth keeping an eye on from period to period and make necessary adjustments if necessary. Exhibit 2. FT819 descriptive overview Data: Fate Therapeutics Website Meanwhile, the Phase 1 trial of FATE's FY596 in combination with rituximab exhibited favorable safety data in both the single dose and dual-dose cohorts. Safety data held up well up to 900 million cells per dose, and the higher-dose regime could well be the protocol looking ahead, by estimate. From here FATA will continue to evaluate dosages for maximal therapeutic effect, with the next moves being a 3-dose cohort at a dose of 1.8 billion cells. We are intrigued to observe the outcome of the increased cellular load, particularly as the clinical protocol permits further dose escalation In terms of regulatory catalysts, investors should keep an eye out for the company's FT516 RMAT Type-B multidisciplinary meeting with the FDA this coming quarter. From here we'll have better understanding on the registrational pathways for the off-shelf programs against refractory aggressive B-cell lymphoma. Patients will include those whose disease is refractory or relapsed after previous treatment from other CD19 targeted CAR T-cell therapies. Reconciliations for accurate valuation We've identified a number of adjustments that need to be made in order to accurately value FATE, in order to understand exactly what it is we're buying. Firstly, R&D expenditure came in at $81 million for the quarter, up from $48 million YoY. We argue that R&D expenditure should be capitalized and amortized as an intangible asset, as it is an investment set to create future economic value. This has implications to earnings and investment for the company. However, we also found we can't capitalize FATE's entire R&D spend. Notably, the $33 million YoY increase in R&D stemmed from: $4.9 million increase in employee SBC expense to $13.57 million $9 million increase in spend to third-party professional consultants $8.6 million increase in expenditures for laboratory materials and supplies relating to the manufacture of product candidates and conduct of research activities. Therefore, we can only advocate to capitalize $67.4 million of R&D as an investment, seeing as SBC is an expense in our eyes. This has implications for both earnings and valuation, as discussed below. In addition, the company's drug product manufacturing facility in California has now opened with engineering runs underway. This is a tangible source of value that will supply drug products for companies conducting pivotal trials. In all, the company has $580 million in tangible book value with this included. Exhibit 3. Data & Image: HB Insights Valuation Being a clinical stage biopharma company, valuation ideally comprises a number of factors to obtain a corporate value for the company. However, we aren't confident on the predictability of estimating the prospective value of FATE's pipeline or working in terms of what's 'possible'. Instead, what's real and 'probable' are better terms to work by. With that, we observe corporate valuation in terms of earnings and investment; what's real and what's expected. We record this in shorthand with multiples of book value and earnings estimates. Instead, we are focusing on what we'd be buying today in FATE.
Seeking Alpha • Jul 28

Needham initiates Fate coverage Therapeutics on potential of stem cell therapies

Needham has initiated coverage on Fate Therapeutics (NASDAQ:FATE) with a hold rating citing the potential of its stem cell cancer therapies. Fate develops induced pluripotent stem cell (iPSC) derived cancer therapeutics, primarily NK cells, which can address several challenges in cell therapy. They are off-the-shelf as opposed to current CAR-T therapies and allow for large-scale manufacturing and relatively easier genetic engineering. Analyst Gil Blum wrote, " Fate's lead programs in B-cell lymphomas and acute myeloid leukemia have potential in ~35,000 patients combined and have demonstrated promising early data. Even assuming cellular therapeutic pricing (~$300K in the US) and achievement of significant market penetration, we find FATE shares fully valued at this time." "Early POC was achieved in both BCL and AML. However, questions regarding treatment durability remain. We consider Fate's platform a compelling solution in solid tumors, despite NK iPSCs having low activity at baseline. Reports of clinical activity in solid tumors could be transformational for Fate," Blum adds. Needham's neutral rating on FATE is in line with SA Quant rating of hold. Shares dipped -5.46% to $31.36 today
Seeking Alpha • Jun 30

Fate Therapeutics names Brian Powl as chief commercial officer

Fate Therapeutics (NASDAQ:FATE) has appointed Brian Powl as its new chief commercial officer. He was most recently SVP, commercial development & marketing at MEI Pharma (MEIP). Before then, he was VP, global commercial CAR T lead at Celgene Corp.

Rentabilidad de los accionistas

FATEUS BiotechsMercado US
7D28.2%1.2%1.1%
1Y94.0%34.6%28.7%

Rentabilidad vs. Industria: FATE superó a la industria US Biotechs, que obtuvo un rendimiento del 34.6% el año pasado.

Rentabilidad vs. Mercado: FATE superó al mercado US, que obtuvo un rendimiento del 28.7% el año pasado.

Volatilidad de los precios

Is FATE's price volatile compared to industry and market?
FATE volatility
FATE Average Weekly Movement16.2%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Precio estable de las acciones: El precio de las acciones de FATE ha sido volátil durante los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de FATE(16%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
2007161Bob Valamehrwww.fatetherapeutics.com

Fate Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica que desarrolla inmunoterapias celulares programadas contra el cáncer y los trastornos inmunitarios en Estados Unidos y a escala internacional. Entre sus productos candidatos de células NK y T dirigidos a receptores de antígenos quiméricos (CAR) figuran el FT836, en fase preclínica para múltiples tipos de tumores, y el FT522, para tratar el linfoma de células B y la autoinmunidad. Sus programas de CAR de células T incluyen FT819 para tratar el lupus eritematoso sistémico, FT839, para tratar enfermedades autoinmunes complejas, y FT825 para tratar tumores sólidos.

Resumen de fundamentos de Fate Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Fate Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de FATE
Capitalización bursátilUS$262.26m
Beneficios(TTM)-US$129.91m
Ingresos (TTM)US$6.32m
41.5x
Ratio precio-ventas (PS)
-2.0x
Ratio precio-beneficio (PE)

¿Está FATE sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de FATE
IngresosUS$6.32m
Coste de los ingresosUS$87.47m
Beneficio bruto-US$81.15m
Otros gastosUS$48.76m
Beneficios-US$129.91m

Últimos beneficios comunicados

Mar 31, 2026

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)-1.11
Margen bruto-1,284.83%
Margen de beneficio neto-2,056.79%
Ratio deuda/patrimonio0%

¿Cómo se ha desempeñado FATE a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/24 15:29
Precio de las acciones al final del día2026/05/22 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Fate Therapeutics, Inc. está cubierta por 26 analistas. 11 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Jack AllenBaird
Tazeen AhmadBofA Global Research
Amanda MurphyBTIG